PD-1 inhibitor

Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors
Shiro Matsubara, Morinobu Seki, Shigeaki Suzuki, Takashi Komori, Mikio Takamori

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 256; DOI: 10.1186/s40425-019-0736-4
Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells
Wanfeng Gao, Xiaoyun Zhang, Wendong Yang, Daolei Dou, Heng Zhang, Yuanhao Tang, Weilong Zhong, Jing Meng, Yun Bai, Yanrong Liu, Lan Yang, Shuang Chen, Huijuan Liu, Cheng Yang, Tao Sun

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 231; DOI: 10.1186/s40425-019-0676-z
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 24; DOI: 10.1186/s40425-019-0514-3
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Gabriele Madonna, Lucia Festino, Antonio Maria Grimaldi, Vito Vanella, Ester Simeone, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Corrado Caracò, Paolo Antonio Ascierto

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 74; DOI: 10.1186/s40425-018-0383-1
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 8; DOI: 10.1186/s40425-018-0316-z
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao, Ranee Mehra, Colleen Veloski

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 40; DOI: 10.1186/s40425-017-0245-2
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone
Samuel Rosner, Filiz Sen, Michael Postow

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 34; DOI: 10.1186/s40425-017-0236-3
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu, Pasi A. Jänne, F. Stephen Hodi, Mark M. Awad

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 84; DOI: 10.1186/s40425-016-0193-2
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab
Matthew Zibelman, Natasha Pollak, Anthony J Olszanski

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 8; DOI: 10.1186/s40425-016-0114-4
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma
Joshua S Manusow, Leila Khoja, Nataly Pesin, Anthony M Joshua, Efrem D Mandelcorn

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 41; DOI: 10.1186/s40425-014-0041-1

Log in using your username and password

Main menu

Log in using your username and password

You are here

PD-1 inhibitor